Dechra Pharmaceuticals PLC
LSE:DPH
Dechra Pharmaceuticals PLC
LSE:DPH
Price:
3 866 GBX
Updated:
May 20, 2024
Dechra Pharmaceuticals PLC
Research & Development
|
Dechra Pharmaceuticals PLC
Research & Development Peer Comparison
Comparables:
GSK
AZN
VRNA
INDV
HIK
Competitive Research & Development Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
Research & Development
-£57.5m
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
-22%
|
|
|
GlaxoSmithKline PLC
LSE:GSK
|
Research & Development
-£5.9B
|
CAGR 3-Years
-9%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-6%
|
|
|
AstraZeneca PLC
LSE:AZN
|
Research & Development
-$10.7B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-9%
|
|
|
Verona Pharma PLC
NASDAQ:VRNA
|
Research & Development
-$17.2m
|
CAGR 3-Years
27%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Indivior PLC
LSE:INDV
|
Research & Development
-$107m
|
CAGR 3-Years
-40%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
N/A
|
|
|
Hikma Pharmaceuticals PLC
LSE:HIK
|
Research & Development
-$149m
|
CAGR 3-Years
-3%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-14%
|
See Also
What is Dechra Pharmaceuticals PLC's Research & Development?
Research & Development
-57.5m
GBP
-57.5m
GBP
Based on the financial report for Jun 30, 2023, Dechra Pharmaceuticals PLC's Research & Development amounts to -57.5m GBP.
What is Dechra Pharmaceuticals PLC's Research & Development growth rate?
Research & Development CAGR 10Y
-22%
-22%
Over the last year, the Research & Development growth was -77%. The average annual Research & Development growth rates for Dechra Pharmaceuticals PLC have been -27% over the past three years , -26% over the past five years , and -22% over the past ten years .
You don't have any saved screeners yet
